Catheter Precision, Inc.

Catheter Precision maintains a capital structure characterized by significant leverage relative to its equity base, with a debt-to-equity ratio of 0.44. The company holds $88,000 in cash and equivalents against $3.08 million in long-term debt, resulting in a negative net cash position. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied to be tight given the low cash balance relative to total liabilities of $9.21 million. The market capitalization stands at $485,864, trading at a price-to-book ratio of 0.07, indicating the market values the company at a steep discount to its tangible book value.

Profitability metrics are deeply negative, reflecting the company's pre-profitability stage. Return on equity is -2.44 and return on assets is -1.08, driven by an operating income loss of $21.14 million against revenue of $819,000. While the gross profit is $756,000, representing a high gross margin, the operating expenses far exceed this contribution, leading to a net income loss of $17.18 million. The company generates negative operating cash flow of $8.30 million, with minimal capital expenditures of $17,000, suggesting that cash burn is primarily driven by operating costs rather than asset investment.

Revenue concentration is a notable feature of the business model. During fiscal 2025, two individual customers accounted for approximately 28% and 12% of total revenues, respectively. This high degree of customer concentration exposes the company to significant downside risk if either major client reduces purchasing volume or terminates the relationship. The revenue mix is not further detailed by segment in the available data, but the reliance on a small number of counterparties is a key structural characteristic.

The growth trajectory is difficult to assess due to the absence of historical period data in the input. The latest reported revenue is $819,000, which matches the last actual revenue estimate. Without multi-year historical data, it is not possible to determine year-over-year growth rates or trend consistency. The company remains in an early stage of commercialization, as evidenced by the small revenue base relative to the scale of operating losses.

Risk factors include medium liquidity risk and low dilution risk. The key flag is the negative net cash position after subtracting total debt, which limits financial flexibility. The low dilution risk suggests that the company has not recently engaged in significant equity issuances, although the negative cash flow may necessitate future capital raises. The company's small market cap and negative earnings make it susceptible to high volatility and potential delisting risks if financial covenants are breached.

Recent events include the termination of a joint marketing agreement with Stereotaxis, Inc. in December 2024. This strategic shift may impact future distribution channels or collaborative development efforts. No other significant news events, filing observations, or transcript observations are present in the data to provide further context on recent operational changes or management guidance.

Catheter Precision Inc. (VTAK.O) has recorded three new institutional holdings, marking a notable shift in its investor base. The most significant addition is a position of 47,659 shares, valued at approximately $48,135, established by an investor as of March 31, 2026. This represents the largest single new stake among the recent changes, indicating a concentrated entry by a specific fund or entity. In addition to the primary addition, two other investors initiated positions during the same reporting period. One investor acquired 15,660 shares, valued at roughly $28,658, with the position recorded as of December 31, 2025. Another investor added a smaller stake of 759 shares, valued at approximately $767, also as of March 31, 2026. These additions collectively expand the company's holder count to four top holders. The significance of these changes lies in the fact that this is the first analysis for this ticker, meaning there is no prior basis for computing deltas in ownership or financial metrics. Consequently, these new entries establish the initial baseline for institutional interest in Catheter Precision Inc. The absence of prior data points makes these fresh additions the primary indicator of current market attention. Despite the new institutional activity, the company currently lacks coverage from financial analysts and is not included in any major indices. With zero officers listed in the current dataset and no analyst estimates available, the new holdings represent the only visible signal of external engagement. Investors should monitor whether these initial stakes grow or if additional institutional interest emerges in future reporting periods.